Parameters | Progression-Free Survival | Cancer-Specific Survival | Overall Survival | |||
---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) P-value | HR (95% CI) | P-value | ||
Age (years) | 0.969 (0.948–0.990) | 0.004 | 0.971 (0.944–1.000) | 0.050 | 0.988 (0.962–1.015) | 0.396 |
PSA (μg/L) | 1.000 (1.000–1.001) | 0.228 | 1.000 (1.000–1.001) | 0.273 | 1.000 (0.999–1.001) | 0.611 |
Gleason Score |  | < 0.001 |  | < 0.001 |  | < 0.001 |
  ≤ 7 | 1 |  | 1 |  | 1 |  |
  > 7 | 2.907 (2.006–4.211) |  | 6.425 (3.265–12.643) |  | 4.740 (2.733–8.220) | |
Metastasis |  | < 0.001 |  | < 0.001 |  | < 0.001 |
 No | 1 |  | 1 |  | 1 |  |
 Yes | 3.528 (2.443–5.096) |  | 7.920 (4.024–15.589) |  | 4.122 (2.496–6.809) |  |
Risk Stratification | Â | 0.023 | Â | 0.069 | Â | 0.095 |
 Lowintermediate | 1 |  | 1 |  | 1 |  |
 High | 2.428 (1.133–5.205) | 24.120 (0.779–746.903) |  | 2.357 (0.861–6.447) | ||
PNI |  | 0.004 |  | 0.001 |  | < 0.001 |
  < 50.2 | 1 |  | 1 |  | 1 | |
  ≥ 50.2 | 0.590 (0.414–0.841) |  | 0.391 (0.226–0.676) |  | 0.407 (0.250–0.662) |  |